Literature DB >> 19073875

Comparison of a commercial real-time PCR assay for tcdB detection to a cell culture cytotoxicity assay and toxigenic culture for direct detection of toxin-producing Clostridium difficile in clinical samples.

Paul D Stamper1, Romina Alcabasa, Deborah Aird, Wisal Babiker, Jennifer Wehrlin, Ijeoma Ikpeama, Karen C Carroll.   

Abstract

Rapid detection of toxin-producing strains of Clostridium difficile is essential for optimal management of patients with C. difficile infection. The BD GeneOhm (San Diego, CA) Cdiff assay, a real-time PCR assay that amplifies tcdB, was compared to a cell culture neutralization assay (Wampole C. difficile Toxin B [TOX-B] test; TechLab, Blacksburg, VA) and to toxigenic culture. Using liquid (n = 273) and soft (n = 131) stool specimens from 377 symptomatic patients, all testing was performed on the same day by independent laboratory staff according to the manufacturers' protocols. Toxigenic bacterial culture was performed as follows. A 0.5-ml aliquot of stool was heated to 80 degrees C for 10 min, followed by inoculation onto modified cycloserine cefoxitin fructose agar with and without horse blood (Remel, Lenexa, KS) and into prereduced chopped-meat broth. Of the 404 stool specimens tested, 340 were negative and 40 were positive (10.0% prevalence) both by PCR for tcdB and by cytotoxin production. The overall agreement between the BD GeneOhm Cdiff assay and the TOX-B test was 94.8% (380/401). When the TOX-B test was used as the reference method, the initial sensitivity, specificity, and positive and negative predictive values of the BD GeneOhm Cdiff assay were 90.9% (40/44), 95.2% (340/357), 70.2% (40/57), and 98.8% (340/344), respectively. When toxigenic culture was used as the "gold standard," the sensitivity, specificity, and positive and negative predictive values of the BD GeneOhm Cdiff assay were 83.6%, 98.2%, 89.5%, and 97.1%, respectively, and those of the TOX-B test were 67.2%, 99.1%, 93.2%, and 94.4%, respectively. PCRs for three samples were inhibited upon initial testing; one sample was resolved upon retesting. One sample produced nonspecific cytotoxin results. The BD GeneOhm Cdiff assay performed well compared to a standard cell culture neutralization assay and to toxigenic culture for the detection of toxigenic C. difficile directly from fecal specimens.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19073875      PMCID: PMC2643696          DOI: 10.1128/JCM.01613-08

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  32 in total

1.  Variant toxin B and a functional toxin A produced by Clostridium difficile C34.

Authors:  M Mehlig; M Moos; V Braun; B Kalt; D E Mahony; C von Eichel-Streiber
Journal:  FEMS Microbiol Lett       Date:  2001-05-01       Impact factor: 2.742

2.  Development and evaluation of a PCR method for detection of the Clostridium difficile toxin B gene in stool specimens.

Authors:  C Guilbault; A-C Labbé; L Poirier; L Busque; C Béliveau; M Laverdière
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

3.  Multicenter evaluation of the Clostridium difficile TOX A/B TEST.

Authors:  D M Lyerly; L M Neville; D T Evans; J Fill; S Allen; W Greene; R Sautter; P Hnatuck; D J Torpey; R Schwalbe
Journal:  J Clin Microbiol       Date:  1998-01       Impact factor: 5.948

4.  Comparison of the VIDAS Clostridium difficile toxin A immunoassay with C. difficile culture and cytotoxin and latex tests.

Authors:  C J Shanholtzer; K E Willard; J J Holter; M M Olson; D N Gerding; L R Peterson
Journal:  J Clin Microbiol       Date:  1992-07       Impact factor: 5.948

5.  Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile.

Authors:  Lorraine Kyne; Mary Beth Hamel; Rajashekhar Polavaram; Ciarán P Kelly
Journal:  Clin Infect Dis       Date:  2001-12-17       Impact factor: 9.079

6.  Production of a complete binary toxin (actin-specific ADP-ribosyltransferase) by Clostridium difficile CD196.

Authors:  S Perelle; M Gibert; P Bourlioux; G Corthier; M R Popoff
Journal:  Infect Immun       Date:  1997-04       Impact factor: 3.441

7.  Rapid detection of Clostridium difficile in feces by real-time PCR.

Authors:  Simon D Bélanger; Maurice Boissinot; Natalie Clairoux; François J Picard; Michel G Bergeron
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

8.  Performance of the TechLab C. DIFF CHEK-60 enzyme immunoassay (EIA) in combination with the C. difficile Tox A/B II EIA kit, the Triage C. difficile panel immunoassay, and a cytotoxin assay for diagnosis of Clostridium difficile-associated diarrhea.

Authors:  Heather Snell; Meredith Ramos; Sue Longo; Michael John; Zafar Hussain
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

9.  Comparison of four commercially available rapid enzyme immunoassays with cytotoxin assay for detection of Clostridium difficile toxin(s) from stool specimens.

Authors:  C S Merz; C Kramer; M Forman; L Gluck; K Mills; K Senft; I Steiman; N Wallace; P Charache
Journal:  J Clin Microbiol       Date:  1994-05       Impact factor: 5.948

10.  Comparison of real-time PCR for detection of the tcdC gene with four toxin immunoassays and culture in diagnosis of Clostridium difficile infection.

Authors:  Lynne M Sloan; Brian J Duresko; Daniel R Gustafson; Jon E Rosenblatt
Journal:  J Clin Microbiol       Date:  2008-04-23       Impact factor: 5.948

View more
  68 in total

1.  A multiplex, internally controlled real-time PCR assay for detection of toxigenic Clostridium difficile and identification of hypervirulent strain 027/ST-1.

Authors:  A M Hoegh; J B Nielsen; A Lester; A Friis-Møller; K Schønning
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-09-22       Impact factor: 3.267

2.  Successful use of nitazoxanide in the treatment of recurrent Clostridium difficile infection.

Authors:  Fnu Rafiullah; Sunil Kanwal; Usman M Majeed; Mark A Korsten; Faisal H Cheema; Munish Luthra; Muhammad Rizwan Sohail
Journal:  BMJ Case Rep       Date:  2011-11-21

Review 3.  Molecular techniques for diagnosis of Clostridium difficile infection: systematic review and meta-analysis.

Authors:  John C O'Horo; Amy Jones; Matthew Sternke; Christopher Harper; Nasia Safdar
Journal:  Mayo Clin Proc       Date:  2012-07       Impact factor: 7.616

4.  Rapid and sensitive loop-mediated isothermal amplification test for Clostridium difficile detection challenges cytotoxin B cell test and culture as gold standard.

Authors:  Torbjörn Norén; Ingegärd Alriksson; Josefin Andersson; Thomas Akerlund; Magnus Unemo
Journal:  J Clin Microbiol       Date:  2010-11-24       Impact factor: 5.948

5.  Assessment of Clostridium difficile infections by quantitative detection of tcdB toxin by use of a real-time cell analysis system.

Authors:  Alex B Ryder; Ying Huang; Haijing Li; Min Zheng; Xiaobo Wang; Charles W Stratton; Xiao Xu; Yi-Wei Tang
Journal:  J Clin Microbiol       Date:  2010-08-18       Impact factor: 5.948

Review 6.  Recognition and prevention of hospital-associated enteric infections in the intensive care unit.

Authors:  Linda D Bobo; Erik R Dubberke
Journal:  Crit Care Med       Date:  2010-08       Impact factor: 7.598

7.  Rapid detection of toxigenic strains of Clostridium difficile in diarrheal stools by real-time PCR.

Authors:  Frédéric Barbut; Mylena Braun; Béatrice Burghoffer; Valérie Lalande; Catherine Eckert
Journal:  J Clin Microbiol       Date:  2009-02-25       Impact factor: 5.948

8.  Evaluation of diagnostic tests for Clostridium difficile infection.

Authors:  Jonathan Swindells; Nigel Brenwald; Nathan Reading; Beryl Oppenheim
Journal:  J Clin Microbiol       Date:  2009-12-23       Impact factor: 5.948

Review 9.  Clostridium Difficile Infection from a Surgical Perspective.

Authors:  Andreas M Kaiser; Rachel Hogen; Liliana Bordeianou; Karim Alavi; Paul E Wise; Ranjan Sudan
Journal:  J Gastrointest Surg       Date:  2015-04-28       Impact factor: 3.452

10.  Premarket evaluations of the IMDx C. difficile for Abbott m2000 Assay and the BD Max Cdiff Assay.

Authors:  K A Stellrecht; A A Espino; V P Maceira; S M Nattanmai; S A Butt; D Wroblewski; G E Hannett; K A Musser
Journal:  J Clin Microbiol       Date:  2014-02-19       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.